**CB₁ cannabinoid receptor enrichment in the ependymal region of the adult human spinal cord**

Beatriz Paniagua-Torija¹, Angel Arevalo-Martin¹, Isidro Ferrer², Eduardo Molina-Holgado³ & Daniel Garcia-Ovejero³

Cannabinoids are involved in the regulation of neural stem cell biology and their receptors are expressed in the neurogenic niches of adult rodents. In the spinal cord of rats and mice, neural stem cells can be found in the ependymal region, surrounding the central canal, but there is evidence that this region is largely different in adult humans: lacks a patent canal and presents perivascular pseudorosettes, typically found in low grade ependymomas. Using Laser Capture Microdissection, Taqman gene expression assays and immunohistochemistry, we have studied the expression of endocannabinoid system components (receptors and enzymes) at the human spinal cord ependymal region. We observe that ependymal region is enriched in CB₁ cannabinoid receptor, due to high CB₁ expression in GFAP⁺ astrocytic domains. However, in human spinal cord levels that retain central canal patency we found ependymal cells with high CB₁ expression, equivalent to the CB₁HIGH cell subpopulation described in rodents. Our results support the existence of ependymal CB₁HIGH cells across species, and may encourage further studies on this subpopulation, although only in cases when central canal is patent. In the adult human ependyma, which usually shows central canal absence, CB₁ may play a different role by modulating astrocyte functions.

The Endocannabinoid System (ECBS) is formed by lipid ligands (endocannabinoids), the enzymatic machinery for their synthesis and degradation and their specific G-protein coupled CB₁ and CB₂ receptors. The most important endocannabinoids are 2-arachidonoylglycerol (2-AG) and anandamide (AEA)¹. These compounds are involved in the control of neural stem cell biology², and many of their effects are mediated by the cannabinoid receptor CB₁. CB₁ receptor is expressed in all neurogenic niches in rodents, including the ependymal region of the spinal cord (reviewed in³). In this region, that holds neural stem cell potential⁴⁵, a subpopulation of cells expresses high levels of CB₁ receptor (CB₁HIGH cells), and proliferate after lesion or during postnatal development in rats⁶. However, the ependymal region of the adult human spinal cord is strikingly different from that of rodents and other primates: although it contains ependymal cells, lacks a patent central canal and shows perivascular pseudorosettes⁷⁻⁹. This means that observations made in rodents should be validated in human tissue to understand the composition and the regenerative potential of this niche. Here we have explored the presence of the ECBS and searched for an equivalent of rat and mice CB₁HIGH cells in adult human spinal cord.

¹Laboratory of Neuroinflammation, Hospital Nacional de Paraplejicos (SESCAM), Toledo, Spain. ²Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospital de Llobregat, Spain. Correspondence and requests for materials should be addressed to E.M.-H. (email: eduardom@sescam.jccm.es) or D.G.-O. (email: dgarcia@sescam.jccm.es)
**Results and Discussion**

We found that human ependymal region consistently expresses CB₁ cannabinoid receptor (CNR1 gene; Table 1). CB₁ receptor could be the target of locally produced 2-AG, since we also found expression (although non-enrichment) of enzymes related with 2-AG synthesis and degradation: diacylglycerol lipase α (DAGLA), diacylglycerol lipase β (DAGLB), monoacylglycerol lipase (MGLL) and abhydrolase domain-containing proteins – 6 (ABHD6) and –12 (ABHD12). On the contrary, we could not find consistent expression of enzymes related with direct anandamide synthesis or degradation (NAPE-phospholipase D and fatty acid amide hydrolase, respectively). However, it should be noted that alternative enzymatic routes have been described for AEA, involving glycerophosphodiester phosphodiesterase and N-acylethanolamine-hydrolyzing acid amidase that have not been tested here². We also did not find expression of CB₂ cannabinoid receptor or the related GPR55 receptor. In previous works, we observed expression (but not enrichment) of PPAR-α, another cannabinoid-related receptor¹, in human ependymal region⁹.

When compared with ventral horn, only CNR1 (CB₁ receptor) was significantly enriched at the ependymal region (Table 1). Accordingly, we found a strong CB₁ immunoreactivity in central gray matter by immunohistochemistry (Fig. 1B–J). But CB₁ enrichment in adult humans ependyma is not equivalent to that found in rodents: In humans, CB₁ is expressed by astrocytes, forming part of the gliosis that accompanies central canal closure (Fig. 1C–E) and in the GFAP⁺ hypocellular ribbon of perivascular pseudorosettes (Fig. 1F–K) ⁹,¹⁰. CB₁ receptor is also expressed in astrocytes from other spinal cord areas (Fig. 2), and its intensity is apparently related to high GFAP expression. Accordingly, a strong CB₁ expression has been reported in reactive astrocytes of human pathologies like spinocerebellar ataxia ¹¹ or temporal lobe epilepsy ¹². The role of astrocytic CB₁ could be multiple: protection ¹³, metabolism increase ¹⁴, control of inflammation¹⁵–¹⁷, inhibition of glutamate transporters ¹⁸ or release of neurotransmitters such as glutamate¹⁹, ATP and D-serine²⁰.

Interestingly, we obtained some sections from adult individuals in which parts of the central canal were patent. In those sections, we found ependymal cells with high expression of CB₁ receptors lining the canal (Fig. 1L–N), resembling those CB₁ HIGH cells described for rats and mice¹⁰. These cells were mostly GFAP⁺, except for a very dim expression at the apical pole (Fig. 1N), in contrast with strongly GFAP⁺ cells embedded in the ependymal layer (Fig. 1M). Our results support the existence of ependymal CB₁ HIGH cells across species, and may encourage further studies on this subpopulation, although only in cases when there is central canal patency, i.e. childhood and upper cervical levels⁶,⁹. But in the majority of adult ependyma, CB₁ is enriched in astrocyte domains, and cannabinoids may play a different role, that still might be relevant, in terms of homeostasis maintenance and response to injury.

**Methods**

Human tissue was obtained from the HUFA BioBank (Alcorcon, Spain) and the HUB-ICO-IDIBELL BioBank (Hospitalet de Llobregat, Spain). Samples were obtained from donor individuals deceased without clinical or histopathological involvement of the spinal cord (Table 2). Donation always included a written informed consent from donors while alive or from their families after death. Data from donors and handling of samples were carried out after approval by the Clinical Research Ethical Committee (CEIC) in Toledo (Spain), in accordance with the Spanish law and International Guidelines (LOPD 15/1999; RD 1720/2007; Helsinki declaration, 2008).

---

**Table 1. Relative expression of endocannabinoid system related genes in the adult human ependymal region compared with ventral horn.** *Significantly enriched in Ependymal region vs Ventral Horn (Student T-test). ND: Non detected in the Ependymal region of any individual; NCD: Non consistently detected (detected in less than 3 of the 4 individuals).
Figure 1. CB₁ cannabinoid receptor in adult human spinal cord. (A) Myelin staining of a representative thoracic spinal cord section. Square depicts the area shown in (C–E). (B) In low magnification a strong CB₁ immunoreactivity can be found in dorsal horn, lamina X and ventral gray matter. (C–E) Higher magnification of central gray shows CB₁ expression in GFAP⁺ areas surrounding the Vimentin⁻ cells at the ependymary region (EpR). Square highlights the location of a perivascular pseudorosette (PvPR). (F–J) Strong CB₁ immunoreactivity is found at the GFAP⁺ domains around and inside perivascular pseudorosettes, including the GFAP ribbon at the hypocellular region of the pseudorosette (hcr, outlined in white). In PvPRs cells are arranged around a central vessel (I arrow). (K) Quantification supports qualitative observations: CB₁ immunoreactivity is significantly accumulated in GFAP⁺ areas. (L) Detail of the dorsal aspect of an ependymal region with a patent central canal. Square depicts location of images M and N. (M) CB₁HIGH ependymal cells (empty arrows) can be found intermingled with ependymocytes lining the central canal. GFAP⁺ cells contacting central canal lumen (arrowhead) are CB₁⁻. (N) Detail of M, showing a CB₁HIGH cell with a dim staining of GFAP in the apical region. "**" Student, p < 0.001; CC, Central Canal; EpR, ependymal region; hcr, hypocellular region; PvPR, perivascular pseudorosette; WM, white matter. Scale bars: A,B = 1 mm; C–E: 100 μm; F–L = 50 μm; M,N = 25 μm.
Gene expression in human ependymal region. All procedures were performed according to our published protocol. Briefly, fresh frozen spinal cord blocks were cut in 25 μm thick sections and the ependymal region microdissected with a Laser Dissection Microscope. RNA extraction, amplification and reverse transcription were performed as previously described. We also collected microdissected portions of ventral horn, which we used as a non-neurogenic, non-ependymal reference for gene expression.

Gene expression was studied with Taqman PCR Assays (Life Technologies, Madrid, Spain) either incorporated in Taqman Low Density Arrays (DAGLA, #Hs00391374_m1; DAGLB, #Hs00373700_m1; MGLL, #Hs00200752_m1; NAPEPLD, #Hs00419593_m1) or in individual assays (ABHD6, #Hs00977889_m1; ABHD12, #Hs01018047_m1; CNR1, #Hs01038522_s1; CNR2, #Hs00361490_m1; NAPEPLD, #Hs00419593_m1).

Figure 2. CB1 immunoreactivity can be found in astrocytes of other regions in the spinal cord. (A–F) CB1 is expressed in the processes of GFAP⁺ and Vim⁺ astrocytes (arrows) at the dorsolateral white matter. (G–I) A strong CB1 expression can be found in astrocytic processes at the subpial region. Scale bars: 25 μm.
Table 2. Postmortem Spinal Cord tissue samples used for immunohistochemistry (IHC) and/or Laser Capture Microdissection (LCMD).

| Autopsy number | Cause of Death                                      | Gender | Age | Coded as | Postmortem delay | Used for   |
|----------------|-----------------------------------------------------|--------|-----|----------|------------------|------------|
| BC01015        | Unknown. No significant neuropathological alterations in the spinal cord | Male   | 60  | Control  | Unknown          | IHC        |
| BC01684        | Acute Hypoxia-ischemia                              | Male   | 27  | Control  | Unknown          | IHC        |
| A07/00044      | Cardiopulmonary arrest                              | Male   | 39  | Control  | 3h 30min         | IHC        |
| A07/00067      | Refractory septic shock and cardiac arrest. Ischemic cardiopathy | Male   | 47  | Control  | 4h 55min         | IHC        |
| A10/00017      | Hepatic metastasis. Probable pancreatic neoplasia   | Male   | 52  | Control  | 03 h             | IHC        |
| A07/00041      | Multisorganic failure. Gastric tumour               | Male   | 43  | Control  | 5h 55min         | IHC, LCMD  |
| A07/00084      | Refractory septic shock                             | Male   | 46  | Control  | 15h              | IHC, LCMD  |
| A10/00026      | Multisorganic failure. Severe broncopathy          | Male   | 61  | Control  | 3h 55min         | LCMD       |
| A05/00134      | Carcinoma and metastasis. With brain but not spinal cord metastasis. | Female | 32  | Control  | 11 h 45 min      | LCMD       |
| A11/00052      | Endocarditis. No neuropathological features         | Male   | 76  | Control  | 06 h 30 m        | LCMD       |
| A12/00046      | Cardiac arrest. No neuropathological features       | Female | 75  | Control  | 06h 10 m         | LCMD       |

Immunohistochemistry. To improve signal to noise ratio and avoid autofluorescence, we amplified CB1 immunoreactivity using Tyrnside Signal Amplification System (TSA Plus Cya nine 3 System #NEL774001KT, Perkin Elmer, USA). Free floating vibratome sections (40 μm) were rinsed on 0.1 M phosphate-buffered saline containing 0.5% bovine serum albumin + 0.3% Triton X-100. Endogenous peroxidase inhibition and antigen demasking were performed as described. Sections were then blocked with TSA Blocking Solution (45°) and incubated for 2 days with primary antibodies diluted in rinse solution +10% Normal Donkey Serum: guinea pig anti-CB1, (1:2000, #CB1-GP-Af530-1, FSI, Japan), rabbit anti-GFAP (1:2000, #Z0334, DAKO, Spain) and mouse anti-Vimentin (1:300, #M0725, DAKO, Spain). Immunoreactivity was visualized by incubating sections with Alexa 488-, Alexa 555- and Alexa 633- secondary antibodies (1:300, Jackson Immunoresearch, UK) followed by Tyrnside-Cy3 diluted in TSA Amplification Buffer (1:50). Samples were analyzed with a LEICA SP5 confocal microscope. We ruled out the interference of nonspecific staining by omitting primary antibodies. We set the confocal parameters at a point where no signal was observed in these primary antibody controls and those settings were used for all the image acquisitions (Supplementary Figure 1A–F). Furthermore, as discussed in several reports, there is a variety of antibodies against CB1 receptor, and some of them may show non-specific staining. The specificity of CB1 antibody used for this report has been extensively validated by other laboratories and ourselves in previous works. We show here an additional validation in the Supplementary Figure 1 by using immunohistochemistry and TSA amplification on wild type (C57BL/6N) and CB1 knockout mice tissue (kindly donated by Dr. Galve-Roperh). Using restrictive confocal parameters (as we did for humans), we got rid out of autofluorescence, background staining and most of the non-specific staining observed in the knockout mice that, in these conditions, is limited to a dim intracellular neuronal staining, largely different from that observed in the wild type mice (Supplementary Figure 1L-Q). All post-capture image modifications were identically performed for controls, including cropping, noise reduction and minor adjustments to optimize contrast and brightness.

To quantitatively support CB1 enrichment in the astrocytic area, we calculated the fraction of CB1 found in GFAP+ vs GFAP− areas on confocal planes (image size 190 μm x 190 μm) using Fiji (http://fiji.sc/). For this, we outlined GFAP borders using manual Threshold with Otsu Filter and used this ROI on the CB1 image corresponding to the same confocal plane. We measured CB1+ Areas inside and outside the selection (GFAP+ and GFAP− areas, respectively) and expressed them as % of total CB1 staining (Fig. 1K).

FAAH, #Hs01038660_m1; GPR55, #Hs00271662_s1). We used 18S gene as an endogenous control (18S, #Hs00303631_g1). For assays incorporated on TLDAs, we added 1.25 ng cDNA/well. For assays performed individually, we added 1.5 ng cDNA/well. Assays were run on an Applied Biosystems® 7900HT Fast Real-Time PCR System. Data were analysed as described using automatic detection of Ct, normalized with the endogenous gene (ΔCT vs 18S). Only genes expressed in at least three out of four samples were considered as consistently expressed and included in statistics. Enrichment was defined as higher and statistically significant expression in ependymal region vs ventral horn (Student’s t-test with ΔCts, p < 0.05). To obtain folds of enrichment, we used Relative quantity formula, RQ = 2^ΔCt.
References

1. Pertwee, R. G. et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1(1) and CB2(2). Pharmacol Rev 62, 588–631, doi: 10.1124/pr.110.0030036/2/4/588 (2010).

2. Maccarrone, M., Guzman, M., Mackie, K., Doherty, P. & Harkany, T. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci 15, 786–801, doi: 10.1038/nrn3486 (2014).

3. García-Ovejero, D. et al. Neuroimmune interactions of cannabinoids in neurogenesis: focus on interleukin-Ibeta (IL-Ibeta) signalling. Biochem Soc Trans 41, 1577–1582, doi: 10.1042/BST201310198 (2013).

4. Sanz, B. et al. A Mesenchymal-Like ZEB1+ Niche Harbors Dorsal Radial Fibrillary Acidic Protein-Positive Stem Cells in the Spinal Cord. Stem Cells 27, 2272–2273, doi: 10.1002/stem.226 (2009).

5. Weiss, S. et al. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci 16, 7599–7609 (1996).

6. García-Ovejero, D., Arevalo-Martin, A., Paniagua-Torija, B., Sierra-Palomares, Y. & Molina-Holgado, E. A cell population that strongly expresses the CB1 cannabinoid receptor in the ependyma of the rat spinal cord. J Comp Neurol 521, 233–251, doi: 10.1002/cne.23184 (2013).

7. Millhorat, T. H., Kotzen, R. M. & Anzil, A. P. Stenosis of central canal of spinal cord in man: incidence and pathological findings in 232 autopsy cases. J Neuropathol Exp Neurol 36, 716–722, doi: 10.3171/jns.1994.80.4.0716 (1994).

8. Yasui, K., Hashizume, Y., Yoshida, M., Kameyama, T. & Sobue, G. Age-related morphologic changes of the central canal of the human spinal cord. Acta Neuropathol 97, 253–259 (1999).

9. García-Ovejero, D. et al. The ependymal region of the adult human spinal cord differs from other species and shows ependymoma-like features. Brain 138, 1583–1597, doi: 10.1093/brain/awv089 (2014).

10. Alfaro-Cervello, C. et al. The adult macaque spinal cord central canal zona contains proliferative cells and closely resembles the human. J Comp Neurol 522, 1800–1817, doi: 10.1002/cne.23501 (2014).

11. Rodriguez-Cueto, C. et al. Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Br J Pharmacol 171, 1472–1489, doi: 10.1111/bph.12283 (2014).

12. Meng, X. D. et al. Astrocytic expression of cannabinoïd type 1 receptor in rat and human sclerotic hippocampi. Int J Clin Exp Pathol 7, 2825–2837 (2014).

13. Carracedo, A. & Lomeli, C. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochem J 380, 435–440, doi: 10.1042/BJ20031714 (2004).

14. Sanchez, C., Galve-Roperh, I., Rueda, D. & Guzman, M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 54, 834–843 (1998).

15. Molina-Holgado, F., Molina-Holgado, E. & Guaza, C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Thielers murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 433, 139–142, doi: 10.1016/S0014-5793(98)00851-5 (1998).

16. Molina-Holgado, F., Molina-Holgado, E., Guaza, C. & Rothwell, N. J. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res 67, 829–836, doi: 10.1002/jnr.10165 (2002).

17. Molina-Holgado, F. et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 23, 6470–6474, doi: 10.1523/JNEUROSCI.2316-03.2003 (2003).

18. Shivachar, A. C. Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes. Biochem Pharmacol 73, 2004–2011, doi: 10.1016/j.biopha.2004.11.028 (2007).

19. Navarrete, M. & Araque, A. Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68, 113–126, doi: 10.1016/j.neuron.2010.08.00986-6273 (10.1016/j.neuron.2010.08.00986 (2010)).

20. Rasooli-Nejad, S., Palygin, O., Lalo, U. & Pankratov, Y. Cannabinoid receptors contribute to astroglial Ca(2+)-signalling and control of synaptic plasticity in the neocortex. Philos Trans R Soc Lond B Biol Sci 369, 20140077, doi: 10.1098/rstb.2014.0077 (2014).

21. Grimsley, N. L. et al. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J Neurosci Methods 171, 78–86, doi: 10.1016/j.jneumeth.2008.02.0148016-0207(08)00114-3 (2008).

22. Morozov, T. M. et al. Antibodies to cannabinoid type 1 receptor co-localize with stomatin-like protein 2 in mouse brain mitochondria. Eur J Neurol 13, 2381–2348, doi: 10.1111/j.1227-2052 (2006).

23. Hebert-Chateilain, E. et al. Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor. Mol Metab 3, 495–504, doi: 10.1016/j.molmet.2014.03.0072212-8778(14)00074-X (2014).

24. Uchigashima, M. et al. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27, 3653–3676, doi: 10.1523/JNEUROSCI.2334-0714 (2007).

25. Yoshida, T. et al. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 26, 4740–4751, doi: 10.1002/jneu.20140077 (2010).

26. Aguado, T. et al. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci 26, 1551–1561, doi: 2015/1551 (2006).

Acknowledgements

This work was funded by Wings For Life Foundation (Salzburg, Austria) and Fundacion Mutua Madrileña (Madrid, Spain). Laboratory of Neuroinflammation is also supported by Instituto de Salud Carlos III (Ministry of Economy and Competitiveness of Spain). We are grateful to Concepción Sanchez-Caro for technical help and Javier Mazario and Jose Angel Rodriguez-Alfaro at the Microscopy Facilities at the National Hospital for Paraplegics.

Author Contributions

B.P.-T. and D.G.-O. Collection and assembly of data; IF: Provision of study material or patients; A.A.-M., E.M.-H. and D.G.-O. Conception and design, data analysis and interpretation; E.M.-H. and D.G.-O. Financial support; D.G.-O. Manuscript writing. All authors gave their final approval to the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Paniagua-Torija, B. et al. CB₁ cannabinoid receptor enrichment in the ependymal region of the adult human spinal cord. Sci. Rep. 5, 17745; doi: 10.1038/srep17745 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/